AI Article Synopsis

  • Germline mutations in the SDHB gene increase the risk of developing paragangliomas, and this study investigates the cancer risk (penetrance) in a large family with such mutations.
  • After screening 19 family members for SDHB mutations, 14 additional carriers were found, and while three refused clinical checks, 11 agreed to screening.
  • The results indicated that only three out of fifteen mutation carriers had paragangliomas, leading to a lower-than-expected penetrance estimate of 26% at 48 years of age in this family.

Article Abstract

Background: Germline mutations of the succinate dehydrogenase subunit B gene (SDHB) predispose carriers for paragangliomas, and current estimates of the chance of mutation carriers actually developing tumors (penetrance) are high. We evaluate the phenotype and penetrance of a germline SDHB mutation in a large and clinically well-characterized paraganglioma family.

Methods: Following identification of the mutation in a 31 year old index-patient, extensive clinical screening was performed in mutation carriers to evaluate the presence of head and neck, thoracic and abdominal paragangliomas. Presymptomatic DNA testing was performed in 19 family members.

Results: DNA analysis detected 14 further SDHB mutation carriers. Three mutation carriers (median age 78 years) declined clinical surveillance, but had no clinical signs or symptoms associated with paragangliomas. The remaining 11 mutation carriers (mean age 53, range 37-76 years) consented to clinical screening. In only two, aged 43 and 48 years, were subclinical vagal paragangliomas identified.

Conclusions: Only three of the fifteen mutation carriers in this family have developed paraganglioma, which results in a calculated penetrance of 26% at 48 years of age. This figure is lower than current estimates, and we conclude that the co-operation of this family allowed an almost complete attainment of mutation carriers, and the extensive clinical evaluation carried out allowed us to identify all affected individuals.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2891715PMC
http://dx.doi.org/10.1186/1471-2350-11-92DOI Listing

Publication Analysis

Top Keywords

mutation carriers
28
sdhb mutation
12
mutation
10
mutation large
8
carriers
8
current estimates
8
extensive clinical
8
clinical screening
8
clinical
5
low penetrance
4

Similar Publications

Salvage pathway of vitamin B absorption in chickens with mutant tumor virus a receptor.

Poult Sci

December 2024

Department of Agricultural Biotechnology and Research Institute of Agriculture and Life Sciences, Seoul National University, Seoul, Republic of Korea; Department of International Agricultural Technology & Institute of Green Bioscience and Technology, Seoul National University, Pyeongchang, Republic of Korea. Electronic address:

The tumor virus A receptor (TVA), a member of the low-density lipoprotein receptor (LDLR) family, serves as an entry receptor for Avian Leukosis Virus (ALV) subgroups A and K, as well as a receptor for vitamin B bound to transcobalamin. Naturally occurring genetic variants in the TVA gene determine susceptibility or resistance to ALV-A and -K, but the effects of these mutated TVA on vitamin B uptake have not been investigated systemically. We found four TVA variants comprising the wild type (TVA), a single nucleotide polymorphism variant (TVA), and two partial deletions in the splicing branch point region (TVA).

View Article and Find Full Text PDF

Vacuolar protein sorting 13 homolog C was associated with motor progression in Parkinson's disease.

Parkinsonism Relat Disord

December 2024

Department of Neurology and Institute of Neurology, Shanghai Jiao Tong University Medical School Affiliated Ruijin Hospital, Shanghai, China. Electronic address:

Introduction: The SNP rs2414739 of Vacuolar protein sorting 13 homolog C(VPS13C) gene was identified to be linked with Parkinson's Disease (PD).

Objectives: Explore the clinical progression feature of PD patients with rs2414739 variant.

Methods: Longitudinal data were obtained from the Parkinson's Progression Marker Initiative (PPMI) cohorts.

View Article and Find Full Text PDF

Background: A recent case report described an individual who was a homozygous carrier of the APOE3 Christchurch (APOE3ch) mutation and resistant to autosomal dominant Alzheimer's Disease (AD) caused by a PSEN1-E280A mutation. Whether APOE3ch contributed to the protective effect remains unclear.

Method: We generated a humanized APOE3ch knock-in mouse and crossed it to an amyloid-β (Aβ) plaque-depositing model.

View Article and Find Full Text PDF

Background: Autosomal dominant Alzheimer's Disease (ADAD) represents around 0.5% of all AD cases, and is caused by mutations in PSEN1, PSEN2 and APP genes. Gene expression studies can be useful for unravelling the physiopathology of AD and identifying potential biomarkers.

View Article and Find Full Text PDF

Basic Science and Pathogenesis.

Alzheimers Dement

December 2024

Brain Research Institute, Niigata University, Niigata, Niigata, Japan.

Background: Recent single-cell omics analyses have revealed that microglia change into reactive microglia when Aβ accumulates in the brain and exhibit Aβ phagocytosis. However, reactive microglia are less likely to be induced in TREM2 mutation carriers. This microglia-centred pathological mechanism may be considered one of the pathologies of AD.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!